Viracta Therapeutics (VIRX)
(Delayed Data from NSDQ)
$0.82 USD
-0.01 (-0.88%)
Updated Apr 29, 2024 03:53 PM ET
After-Market: $0.84 +0.02 (2.31%) 6:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Price, Consensus and EPS Surprise
VIRX 0.82 -0.01(-0.88%)
Will VIRX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VIRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VIRX
Has IMARA (IMRA) Outpaced Other Medical Stocks This Year?
Does Sunesis (VIRX) Have the Potential to Rally 335% as Wall Street Analysts Expect?
VIRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viracta (VIRX) Up on Orphan Drug Tag for Peripheral Lymphoma
Here's Why Viracta Therapeutics (VIRX) is Up So Far This Year
Here's Why Assertio Holdings (ASRT) Stock is Up This Year
Other News for VIRX
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Day One wins FDA nod for brain cancer therapy, Ojemda
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
Promising Clinical Trial Results Reinforce Buy Rating for Viracta Therapeutics